Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 3/20 | 0.53 |
| ▸ | ATR | Q13535 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MELK | Q14680 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1257965 | 0.86 | DRD2 (0.43) | KDRFYNATR | |
| SCHEMBL14674382 | 0.85 | CD274 (0.67) | KDRFYNATRCD274MELK | |
| SCHEMBL1256254 | 0.81 | KDR (0.57) | KDRFYNATRCD274MELK | |
| SCHEMBL3249454 | 0.81 | KDR (0.57) | KDRFYNATRCD274MELK | |
| SCHEMBL15962681 | 0.81 | KDM4E (0.49) | FYNTSHRNPC1RAB9ACNR1 | |
| SCHEMBL1257973 | 0.80 | FLT3 (0.66) | KDR | |
| Hydrochloric Acid SCHEMBL1257055 | 0.80 | KDR (0.56) | KDRFYNATRCD274MELK | |
| SCHEMBL3244400 | 0.79 | FYN (0.54) | KDRFYNATRMELK | |
| SCHEMBL1255981 | 0.78 | FLT3 (0.49) | KDRFYN | |
| SCHEMBL1257378 | 0.78 | FLT3 (0.48) | KDRFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011022473-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | FLT3, CSF3R, CSF1R | KDR 27/4885FYN 137/4885ATR 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.